SAT0152 A Randomised, Double-Blind, Phase III Study Comparing SB2, An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Autor:	J.-Y. Choe, N. Prodanovic, J. Niebrzydowski, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekic, W. Porawska, H. Ciferska, K. Jedrychowicz-Rosiak, A. Zielinska, J.Y. Bang, Y.H. Rho, J.S. Smolen
Rok vydání:	2015
Předmět:	Rheumatology Immunology Immunology and Allergy General Biochemistry Genetics and Molecular Biology
Zdroj:	Annals of the Rheumatic Diseases. 74:706.3-707
ISSN:	1468-2060 0003-4967
DOI:	10.1136/annrheumdis-2015-eular.1583
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ca7715f6f203d57738ea352a19a1e245 https://doi.org/10.1136/annrheumdis-2015-eular.1583 Zobrazit plný text záznamu